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The striatum plays a central role in motor control and motor learning. Appropriate
responses to environmental stimuli, including pursuit of reward or avoidance of aversive
experience all require functional striatal circuits. These pathways integrate synaptic inputs
from limbic and cortical regions including sensory, motor and motivational information
to ultimately connect intention to action. Although many neurotransmitters participate in
striatal circuitry, one critically important player is acetylcholine (ACh). Relative to other brain
areas, the striatum contains exceptionally high levels of ACh, the enzymes that catalyze
its synthesis and breakdown, as well as both nicotinic and muscarinic receptor types that
mediate its postsynaptic effects. The principal source of striatal ACh is the cholinergic
interneuron (ChI), which comprises only about 1–2% of all striatal cells yet sends dense
arbors of projections throughout the striatum. This review summarizes recent advances
in our understanding of the factors affecting the excitability of these neurons through
acute effects and long term changes in their synaptic inputs. In addition, we discuss the
physiological effects of ACh in the striatum, and how changes in ACh levels may contribute
to disease states during striatal dysfunction.
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INTRODUCTION
The striatum is a subcortical brain region crucial for integrat-
ing motivation and action (Da Cunha et al., 2012). Convergence
of inputs from motor cortex, thalamus and limbic areas cre-
ate associations between actions and outcomes that ultimately
contribute to survival. The essential nature of the striatum is
evidenced by the presence of homologs structures through-
out vertebrate evolution over hundreds of millions of years
(Stephenson-Jones et al., 2011). Pathological changes in the stria-
tum and associated basal ganglia structures are implicated in
a wide variety of neurological and psychiatric disorders that
involve the combination of motivation and action, including
drug addiction (Koob, 1992), binge-eating (Norgren et al., 2006),
obsessive-compulsive disorder (Aouizerate et al., 2004), atten-
tion deficit and hyperactivity disorder (Chudasama and Robbins,
2006), Huntington’s disease (Cepeda et al., 2007), Parkinson’s
disease (Albin et al., 1989; Ellens and Leventhal, 2013), and L-
DOPA induced dyskinesia (Barroso-Chinea and Bezard, 2010).
Because so many human pathologies involve striatal dysfunc-
tion, a better understanding of neurotransmission in this brain
structure will provide insight into the etiology of these condi-
tions, potentially leading to the development of new pharma-
cotherapies. One neurotransmitter that is highly enriched in the
striatum and vitally important for normal function is acetyl-
choline (ACh). This review will focus on the regulation of striatal
ACh release as well as the functional consequences of cholinergic
neurotransmission.
Unlike brain structures that show ordered laminar organiza-
tion such as the hippocampus or cortex, the striatum is a hetero-
geneous mix of different cell types. The vast majority of striatal
neurons (∼95%) are the GABA-ergic medium spiny neurons
(MSNs), also referred to as spiny projection neurons, which are
the principal output cell type. The MSNs that express dopamine
(DA) D1 receptors project to and inhibit cells in the internal cap-
sule of the globus pallidus as well as the substantia nigra pars
reticulata. These projections are referred to as the direct path-
way, or the GO pathway, and activation of this class of cells leads
to enhanced locomotion. Another MSN population expresses
dopamine D2 receptors, and these projections inhibit cells in the
external capsule of the globus pallidus. This is the indirect, or
the NO-GO pathway, and activation of this pathway decreases
locomotion. Both pathways eventually influence thalamic control
of motor cortex to affect motor function. Approximately 6% of
MSNs in the dorsal striatum express both D1 and D2 receptors.
These cells produce both GABA and glutamate, allowing them
to potentially modulate the basal ganglia network bidirectionally
(Perreault et al., 2012). The MSN network of basal ganglia con-
nectivity has provided a model for understanding striatal involve-
ment in motor control (Albin et al., 1989; DeLong, 1990; Kravitz
et al., 2010). In addition to the MSNs, approximately 4% of stri-
atal neurons are GABA-ergic interneurons. These locally project-
ing inhibitory cells consist of three types: parvalbumin-expressing
fast spiking interneurons (FSIs), NPY/SOM/NOS-expressing per-
sistent depolarization low-threshold spiking interneurons, and
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the less understood calretinin-expressing low-threshold calcium
spike interneurons (Kawaguchi, 1993). Each of these GABA-
interneuron cell types possesses a unique gene expression profile
and distinct electrophysiological properties (Tepper et al., 2010).
The remaining cells are the large, aspiny cholinergic interneu-
rons (ChIs) originally described by the anatomist Kölliker in the
late 1800’s. Although recent tract tracing and electronmicroscopy
studies report cholinergic projections from the rostral pedun-
culopontine nucleus into the striatum (Dautan et al., 2014), it
is generally accepted that ChIs are the main source of striatal
ACh (Woolf and Butcher, 1981). ChIs comprise ∼1% of stri-
atal cells, yet they ramify extensively and send projections widely
throughout the striatum: each ChI is estimated to produce on
average 500,000 axonal varicosities (Bolam et al., 1984; Contant
et al., 1996). Anatomically, ChIs are easily distinguished from
the other striatal cell types due to their large diameter somata
(>15 microns). In addition, ChIs display unique electrophysio-
logical characteristics, which include tonic action potential firing
at a rate of 3–10Hz (Wilson et al., 1990), depolarized rest-
ing membrane potential (∼ −60mV) (Lee et al., 1998), high
input resistance (∼ 200M) (Calabresi et al., 1997), promi-
nent hyperpolarization-activated cation current (Ih) (Deng et al.,
2007a), and broad action potential duration (Threlfell et al.,
2012). The striatum has the highest levels of cholinergic mark-
ers in the brain, including ACh, choline acetyltransferase (ChAT),
and acetylcholinesterase (AChE) (Macintosh, 1941; Hebb and
Silver, 1961; Woolf et al., 1984). Such a high density of choliner-
gic markers underscores the importance of ACh neurotransmis-
sion in the striatum. Therefore, understanding striatal physiology
requires careful consideration of the activity of ChIs and the
consequences of changes in cholinergic signaling.
Classically, the striatum is subdivided according to synap-
tic connectivity. For example, the dorsal striatum receives DA-
ergic input primarily from substantia nigra pars compacta (SNc)
(Hattori et al., 1991) and sends projections to ventrolateral sub-
stantia nigra pars reticulata (SNr) and the globus pallidus. The
ventral striatum receives the majority of DA from ventral tegmen-
tal area (VTA) projections, and in turn, sends inhibitory pro-
jections into the dorsomedial SNr (Maurin et al., 1999) and
globus pallidus. In rodents, the dorsal and ventral striatum sub-
serve different functions: The dorsal striatum is implicated in
sensorimotor functions such as serial order learning (Yin, 2010),
stimulus-response habit formation (Devan et al., 2011), and per-
formance of learned instrumental tasks (Shiflett et al., 2010),
whereas the ventral striatum is important for the reinforce-
ment of appetitive behaviors including drugs of abuse (Robinson
and Berridge, 2000) and healthy rewards, such as food intake
(Kelley, 2004). Different functional roles are attributed to lateral
vs. medial regions of the dorsal striatum. The dorsolateral region,
or the “sensorimotor striatum,” receives strong motor and pre-
motor cortical inputs, and is therefore particularly important for
habit formation (Künzle, 1975; Haber et al., 2000). The dorso-
medial striatum, referred to as the “associative striatum,” receives
inputs from limbic regions as well as prefrontal cortex, and is
involved in behavioral flexibility, reward-associated motor learn-
ing, and reaction time (Hauber and Schmidt, 1994; Ragozzino,
2003). Gradients of afferent connectivity most likely influence
overall striatal output (Voorn et al., 2004), suggesting that these
subdivisions are an oversimplification of striatal connectivity and
function. Accepting that caveat, the distinctions in function of dif-
ferent striatal regions in the rodent brain provide a framework
for ongoing investigations into the neural substrates of relevant
behaviors, with an ultimate goal of understanding the functional
role of analogous structures in the human brain.
ChIs are believed to be the analogs of tonically active neu-
rons (TANs) identified by in vivo recordings in the putamen
of primates. This correlation is based on similarities in ChAT
immunoreactivity, electrophysiological, and morphological char-
acteristics (Inokawa et al., 2010). Changes in TAN activity have
been linked to motor and reinforcement learning. In classical sen-
sorimotor Pavlovian conditioning, TANs pause activity within
a second after presentation of the conditioned stimulus (CS),
followed by a transient increase in activity before recovery to
baseline firing. This stereotyped neural behavior was described
as the “conditioned pause response” (Kimura et al., 1984; Aosaki
et al., 1994). This CS-induced change in firing is not depen-
dent on motor activity, as a similar firing profile was observed
when the animal was trained to withhold movement after CS
presentation in a NO-GO task (Apicella et al., 1991). TANs also
pause in response to aversive-CS, but not to neutral stimuli (Ravel
et al., 1999). The conditioned pause response is therefore believed
to encode salience value to external stimuli. Thus, changes in
TAN activity may contribute to associative learning, particularly
the relationship between environmental cues and outcomes. The
circuitry responsible for the pause response is debated. Some evi-
dence implicates a dependence on SNc DA-ergic tone (Watanabe
and Kimura, 1998; Reynolds et al., 2004; Straub et al., 2014),
however others have observed a change in TAN firing even in
response to aversive stimuli that do not increase DA-ergic fir-
ing (Mirenowicz and Schultz, 1996; Ravel et al., 1999). We know
that ChIs respond to many neurotransmitters, and this stereotyp-
ical pause in activity could be mediated by a variety of inputs.
Synchronous changes in afferent activity likely mediate the pause
response among multiple ChIs, resulting in a coordinated change
in striatal cholinergic tone. Understanding the connectivity and
neurotransmission that influences these cells may thus provide
insight into learning phenomena.
STRIATAL CHOLINERGIC DYSFUNCTION IN PARKINSON’S
DISEASE AND TREATMENT
The necessity of proper striatal neurotransmission for normal
motor function is dramatically and tragically evidenced by the
deficits observed in Parkinson’s disease (PD). The first medical
characterization of PD was published in 1817 (Parkinson, 1817):
The first symptoms perceived are, a slight sense of weakness, with
a proneness to trembling in some particular part; sometimes in the
head, but most commonly in one of the hands and arms. . . After a
fewmore months the patient is found to be less strict than usual in
preserving an upright posture: this being most observable whilst
walking.
Although this is the first formal description of the disease in
Western literature, descriptions of the disease appeared in Eastern
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texts as old as 600 BC (Manyam, 1990; Zhang et al., 2006;
Raudino, 2012; Ovallath and Deepa, 2013). Some ancient cultures
used treatments derived from herbal preparations that contain
anticholinergic compounds with similar pharmacology to some
therapies prescribed today (Manyam and Sánchez-Ramos, 1999).
Today, we know that the bradykinesia, resting tremor, rigid-
ity, and difficulty in initiating movement observed in PD arise
from deficits in basal ganglia DA transmission. However, it is
important to consider the balance between the actions of stri-
atal ACh and DA in the etiology of PD. Previous beliefs held
that the two neurotransmitters had opposing actions, which was
supported by the partial relief of PD symptoms with administra-
tion of anticholinergic compounds. These therapies may restore
the balance between the two neurotransmitter systems. Drugs
with similar pharmacological properties are still in use, particu-
larly for younger PD patients whose primary symptom is tremor
(Hristova and Koller, 2000), but cognitive and autonomic side
effects preclude their widespread use. While anticholinergic drugs
can improve some symptoms of PD (Whyte et al., 1971; Cantello
et al., 1986; Baba et al., 2012), it has also been reported that
elevation of ACh by treating patients with acetylcholinesterase
inhibitors improves motor symptoms of PD (Chung et al., 2010).
Although somewhat contradictory to the anticholinergic drug
effects, inhibiting ACh degradation might enhance DA transmis-
sion through nicotinic acetylcholine receptors (nAChRs) on DA
terminals. Alternatively, this treatment could promote choliner-
gic receptor desensitization to mimic anticholinergic drug effects.
It is important to note that similar cholinesterase treatments
have seen no effect on motor symptoms of PD (Poewe et al.,
2006). Together, these observations highlight the importance of
cholinergic transmission in striatal function under healthy and
Parkinsonian conditions.
The physiology of ChIs is dramatically altered in PD. In
humans, mutations in leucine-rich repeat kinase 2 (LRRK2) or
the gene that encodes α-synuclein are both associated with a
higher likelihood to develop PD (Simón-Sánchez et al., 2009).
These genes are expressed in many basal ganglia cell types and
the mechanisms that link these mutations to PD are the subject of
ongoing studies (Gasser, 2009). ChIs in both rodents and humans
express high levels of LRRK2 (Higashi et al., 2007; West et al.,
2014), and abnormal kinase activity may contribute to patho-
logical changes in ChI physiology. α-synuclein inclusions in the
somata of ChIs are observed only in late PD but not early PD
(Mori et al., 2008), suggesting that Lewy body-related interference
of ChI physiology may be observed late in the disease.
In the 6-OHDA lesion model of PD, microdialysis studies have
observed that striatal ACh levels are elevated in the DA depleted
rat striatum (DeBoer et al., 1993), indicating a dysregulation of
ChI excitability. Additionally, functional downregulation ofM4—
Cav2 coupling results in decreased sensitivity to autoinhibitory
cholinergic transmission (Ding et al., 2006). Given the therapeu-
tic effects of anticholinergic compounds in PD mentioned above,
and the physiological changes in ChIs seen in animal models of
the disease, it is evident that ACh is important in PD.
The development of DA replacement therapy to relieve the
symptoms of PD in the 1960’s revolutionized our understand-
ing of neurotransmission in the dorsal striatum (Goetz, 2011).
Currently, the biochemical precursor to DA, levodopa (L-DOPA)
is the most effective clinical treatment for the motor symptoms
of PD. L-DOPA crosses the blood brain barrier where it is then
converted into DA by aromatic amino acid decarboxylase, thus
increasing striatal levels of DA. Although L-DOPA effectively
reverses PD locomotor disability, long-term treatment has its
shortcomings, including shortening of the therapeutic window
and psychiatric or mood disturbances such as impulse control
disorders (Lesser et al., 1979; Voon et al., 2009; Santangelo et al.,
2013a,b). Another debilitating side effect is the onset of levodopa-
induced dyskinesia (LID), which is characterized by dystonia or
choreic movements of the limbs, hands, or face. These side effects
are potentially more debilitating than PD itself. This condition
is highly prevalent, with LID development seen in approximately
40% of patients after 5 years of treatment, rising to nearly 90%
after 10 years (Ahlskog and Muenter, 2001; Fabbrini et al., 2007).
Interestingly, the age of onset of PD is a strong determinant for
the development of LID, with earlier onset patients experiencing
a more rapid expression of LID symptoms (Kostic et al., 1991;
Kumar et al., 2005).
Pathological changes in striatal ACh signaling are related to the
expression of LID. The anticholinergic benzatropine decreased
dyskinesia in L-DOPA treated human PD patients (Pourcher
et al., 1989), however, there are also reports of increased dyski-
nesia with anticholinergic treatment (Birket-Smith, 1974; Hauser
and Olanow, 1993; Linazasoro, 1994). In a study of dyskinetic
monkeys, the mAChR antagonist atropine changed the nature
of dyskinesia from dystonia to chorea (Gomez-Mancilla and
Bédard, 1993). Although these reports show mixed effects, they
do suggest that cholinergic signaling influences the expression
of LID. While examining a mouse model of LID, Ding et al.
(2011b) observed enhanced levels of phosphorylated extracellu-
lar signal-regulated kinase (pERK) specifically in striatal ChIs.
Electrophysiological recordings of ChIs revealed higher baseline
and dopamine-induced firing rates in LID animals relative to
vehicle-treated littermates. The increased ChI excitability and the
expression of LID associated behaviors were both inhibited by
blockers of MEK/ERK signaling (Ding et al., 2011b). Extending
those studies, selective ablation of striatal ChIs decreases LID
expression in a unilateral lesion model of PD (Won et al., 2014).
Both nicotinic and muscarinic receptors are believed to con-
tribute to LID. Treatment with either nAChR antagonists or
nicotine improves abnormal involuntary movements (AIMs) in
rodents and primates, which suggests that both drugs are decreas-
ing nAChR function either through receptor blockade or desensi-
tization (Quik et al., 2007; Bordia et al., 2010; Zhang et al., 2013).
Although antimuscarinic drugs have mixed effects in human LID
patients as mentioned above, there are reports of decreased LID
expression (Pourcher et al., 1989), and a recent study of the Pitx3
mouse model of LID, a muscarinic receptor antagonist decreased
behavioral expression of dyskinesia (Ding et al., 2011b). These
findings support the conclusion that cholinergic transmission is
important for mediating some aspects of LID and that pharmaco-
logical modulation of this system may help treat this debilitating
condition.
Changes in striatal cholinergic signaling have been observed in
patients with other movement disorders and psychiatric illnesses.
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A partial list of these disorders and the nature of the changes
in cholinergic activity can be found in Table 1. Considering the
importance of striatal ChIs in both normal physiology and in dis-
ease, it is clear that this minority of cells plays a major role in the
striatum. As such, understanding the nature of efferent and affer-
ent synaptic connectivity of ChIs can provide important insights
into striatal physiology.
AFFERENT CONNECTIONS TO ChIs
ChI excitability is affected by a remarkably large number of
afferent input types and post-synaptic receptors. A simplified
summary of this complex story is presented in Table 2 and
Figures 1, 2. This section outlines the current state of our
understanding of afferent control of ChIs.
GABA
ChIs receive a variety of GABA-ergic inputs, both local and
extrastriatal in origin. GABA can inhibit cells by activating
ionotropic GABAA receptors, which increases Cl- conductance.
Of the GABAA receptor subunits, the α2, α4, β2/3 subunits are
most highly expressed in the striatum (Persohn et al., 1992),
and of potential interest, the α3 subunit is expressed only in
choline acetyltransferase positive (ChAT+) cells (Rodríguez-
Pallares et al., 2000). Local stimulation produces IPSCs in ChIs,
and these events are blocked by bicuculline, indicating that ChIs
express functional GABAA receptors (Sato et al., 2014). GABA
also activates metabotropic GABAB receptors, G-protein coupled
receptors (GPCRs) which decrease cell excitation by coupling to
the Gi/o protein and negatively regulating adenylyl cyclase (AC)
(Bettler et al., 2004). Neither immunohistochemical examina-
tion of GABAB expression in ChIs nor the electrophysiological
effects of selective GABAB activation on ChI excitability have been
reported. In vivo, microdialysis experiments suggest that tonic
activity at GABAA receptors regulates ChI excitability, whereas the
GABAB receptors do not tonically inhibit ChI activity (DeBoer
and Westerink, 1994).
Locally, GABA-ergic MSNs form synaptic connections with
ChIs. Substance P-containing inputs are more prevalent than
enkephalin-containing terminals, perhaps indicating that D1
MSNs have a more prominent influence over ChI activity com-
pared to D2 MSNs (Martone et al., 1992). MSNs in the intact
brain exist in one of two states of excitability, either an up or
down state. In the up state, cells rest at a depolarized mem-
brane potential, and are more likely to fire spontaneous action
potentials compared to the relatively hyperpolarized down state
(Wilson and Groves, 1981). The excitability state of MSNs will
thus influence the inhibitory tone on ChIs. In the slice prepa-
ration MSNs are silent, and GABA released from these neurons
will have minimal impact on ChIs. However, optogenetic acti-
vation of MSNs evoked a small amplitude IPSC in ∼75% of
ChIs, suggesting that theMSN-ChI connection is highly prevalent
(Chuhma et al., 2011). Ultrastructural analysis of TAN connec-
tivity in primates shows that approximately 24% of all synaptic
contacts onto ChAT+ cells originate from MSN axon collaterals
(Gonzales et al., 2013). In sum, GABA release from MSN onto
ChIs is likely a major determinant of excitability of these cells
in vivo.
ChIs also receive synaptic inputs from GABA-ergic interneu-
rons. nAChR activation, presumably located on GABA-ergic
interneurons, inhibits tonic firing of ChIs (De Rover et al., 2002;
Sullivan et al., 2008). Not all GABA-ergic interneurons project
to ChIs, however: PV positive FSIs project to MSNs and other
interneurons, but do not inhibit ChIs (Szydlowski et al., 2013).
Currently, NPY-expressing PLTS GABA-ergic interneurons are
the best candidate for inhibition of ChIs, as ultrastructural anal-
ysis suggests synaptic connections with choline acetyltransferase-
positive striatal neurons (Vuillet et al., 1992). However, there is
no direct electrophysiological or functional evidence for this con-
nection. It is unknown if calretinin positive interneurons form
connections with ChIs.
Extrastriatal sources of GABA may also inhibit ChIs. Co-
release of DA and GABA from nigrostriatal neurons onto MSNs
occurs via a VMAT2-dependent vesicular mechanism (Tritsch
et al., 2012). Cholinergic activation of nAChRs on those termi-
nals was recently shown to enhance GABAergic inputs to MSNs
(Nelson et al., 2014b). We know that DA projections form promi-
nent synaptic contacts onto ChIs (Dimova et al., 1993; Li et al.,
2002), and if some of these DA teminals co-release GABA, these
inputs could profoundly affect tonic activity of ChIs in vivo. In
addition, these projections may also have important implications
in PD, as the loss of SNc projections could decrease this source of
GABA-ergic tone onto ChIs, potentially contributing to increases
in striatal ACh levels. Other non-dopaminergic projection neu-
rons may contribute to GABA inhibition of ChIs. In addition to
DA neurons, the VTA possesses GABA projection neurons that
inhibit ventral striatum ChIs (Brown et al., 2012), but whether
dorsal striatumChIs receive GABA input fromnon-dopaminergic
projection neurons in SNc or VTA is not known. Nigrostriatal
non-dopaminergic projections have been observed (Gerfen et al.,
1987; Rodríguez and González-Hernández, 1999), but the phys-
iological effects of these presumed GABA projections on ChI
activity have not been studied. These extrastriatal GABA projec-
tions may provide a means to inhibit ChIs that is independent of
intrastriatal GABA sources.
GLUTAMATE – IONOTROPIC RECEPTORS
Glutamatergic innervation of ChIs is predominantly extrastri-
atal (Künzle, 1975). Glutamate induces rapid depolarization
through activation of postsynaptically expressed AMPA, NMDA,
or kainate receptors. About half of all ChIs are immunopositive
for GluR1, GluR2, andGluR4 subunits (Bernard et al., 1997; Deng
et al., 2007b), despite the presence ofmRNAof all 4 GluR subunits
(Richardson et al., 2000). AMPA receptors expressed on ChIs
show rapid deactivation, desensitization, and a relatively high per-
meability to Ca2+, and these properties differ from the AMPA
receptors expressed by MSNs (Götz et al., 1997). mRNA for NR1
and NR2D are present at high levels in ChIs, while expression of
NR2AmRNA is contested (Landwehrmeyer et al., 1995; Standaert
et al., 1999; Richardson et al., 2000). 90% of ChIs are immunopos-
itive for the kainate receptors GluR5/6/7 (Chen et al., 1996).
In a slice preparation, bath application of an NMDAR positive
allosteric modulator increases ChI firing rate (Feng et al., 2014),
implying that glutamate tone in the slice preparation contributes
to baseline ChI excitability. Considering the expression of these
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Table 1 | Diseases associated with striatal cholinergic dysfunction.
Disorder Nature of change Species Citations
Parkinson’s disease (PD) Smokers are less likely to develop PD Human Morens et al., 1995; Allam et al., 2004;
Quik et al., 2012
↓ symptoms with anticholinergic
drugs
Human (drug trial) Katzenschlager et al., 2003; Lanska, 2010;
Fox et al., 2011; Fernandez, 2012
↓ AChE activity Human (PET Scan) Gilman et al., 2010
↓ nAChR binding Human (postmortem) Rinne et al., 1991; Aubert et al., 1992;
Court et al., 2000; Hellström-Lindahl and
Court, 2000; Bohr et al., 2005; Gotti et al.,
2006a
Monkey (MPTP lesion) Kulak et al., 2002; Quik and McIntosh,
2006
↓ M1 binding Human (PM) Sirviö et al., 1989; Lange et al., 1993;
Piggott et al., 2003
Changes in CHRNB3 gene Human (genotyping) Bar-Shira et al., 2014
Huntington’s disease ↓ in symptoms with AChE inhibitor Rat (3-NP lesion) Kumar and Kumar, 2009
↓ ChAT activity Human Bird and Iversen, 1974; Enna et al., 1976a;
Suzuki et al., 2001a
↓ ChAT mRNA Mouse (R6/1 model) Smith et al., 2006
↓ mAChR binding Human (postmortem) Hiley and Bird, 1974; Enna et al., 1976a,b
Alzheimer’s disease ↓ cognitive deficits with AChE Rat (ketamine induced behavior) Zugno et al., 2013
↓ AChE levels (in NAc) Human (PM) Hammond and Brimijoin, 1988
↓ nAChR binding sites in putamen,
but not in caudate
Human (postmortem) Shimohama et al., 1985
No change in nAChR binding Human (postmortem) Aubert et al., 1992; Gotti et al., 2006a
↓ cognitive deficits with α7 or α4β2
agonists
Human (drug trial) Haydar and Dunlop, 2010
↑ M1 binding Human (postmortem) Aubert et al., 1992
Schizophrenia ↑ likelihood to smoke Human Dalack et al., 1998; McEvoy and Allen,
2002
↑ ChAT activity Human (postmortem) McGeer and McGeer, 1977
↓ ChAT activity Human (postmortem) Bird et al., 1977
↓ ChAT+ cells Human (postmortem) Holt et al., 1999
↓ cognitive deficits with nicotine,
α4β2 agonist
Human (drug trial) Radek et al., 2010
↑ nAChR binding Human (postmortem) Court et al., 2000
↓ nAChR binding Human (postmortem) Durany et al., 2000
↓ mAChR binding Human (SPECT scan) Raedler et al., 2003
↓ M1 levels Human (postmortem) Dean et al., 1996
Changes in CHNRA7 gene Human (postmortem, genotyping) Leonard et al., 2002
Bipolar disorder ↓ β2* nAChR binding Human (PET scan) Hannestad et al., 2013
Changes in CHRNA7 gene Human (genotyping) Hong et al., 2004; Ancín et al., 2010
Tourette syndrome ↓ ChAT+ cells Human (Postmortem) Kataoka et al., 2010
↓ tics with cholinesterase inhibitor Mouse (DOI induced head tics) Hayslett and Tizabi, 2003
Human (drug trial) Cubo et al., 2008
↓ tics with nicotine Mouse (DOI induced head tics) Hayslett and Tizabi, 2003
Human (drug trial) Shytle et al., 1996; McEvoy and Allen,
2002
↓ tics with nAChR antagonist Mouse (DOI induced head tics) Hayslett and Tizabi, 2003
Human (drug trial) Sanberg et al., 1998; Silver et al., 2000
(Continued)
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Table 1 | Continued
Disorder Nature of change Species Citations
Alternative splicing in ACh related
genes
Human (genotyping) Tian et al., 2011
Attention Deficit
Hyperactivity Disorder
No change in performance on
attention tasks with nAChR agonist
Human (drug trial) Jucaite et al., 2014
↑ performance on attention tasks with
nAChR agonist
Rat (MK801 induced attentional
impairment)
Rezvani et al., 2012
Human (drug trial) Wilens and Decker, 2007; Bain et al.,
2013; Potter et al., 2014
Changes in choline transporter gene Human (genotyping) English et al., 2009
Changes in CHRNA4 gene Human (genotyping) Todd et al., 2003; Lee et al., 2008; Guan
et al., 2009; Wallis et al., 2009
glutamate receptors on ChIs, it is not surprising that applica-
tion of AMPA, NMDA, or kainate excites ChIs (Calabresi et al.,
1998b; Vorobjev et al., 2000; Cepeda et al., 2001). Collectively, the
expression of the three functional classes of glutamate receptors
support the idea that glutamate is an important determinant of
ChI excitability.
Electron microscopy has revealed that glutamate synapses
comprise 13% of total synaptic connections onto ChIs (Gonzales
et al., 2013). In the dorsolateral striatum, glutamate is released
from cells located in the sensorimotor cortex and the centrome-
dian/parafascicular nucleus of the thalamus, with the vast major-
ity of excitatory projections being thalamic in origin (Berendse
and Groenewegen, 1990; Lapper and Bolam, 1992; Thomas et al.,
2000; Ding et al., 2010). Glutamatergic inputs, predominantly
thalamostriatal projections are likely responsible for synchronous
activation of ChIs, which has been suggested to coordinate DA
release through activation of nAChRs on DA terminals (Ding
et al., 2010; Threlfell et al., 2012). Another source of glutamate,
corelease from SNc dopamine terminals, is a topic of debate—
Optogenetic activation of SNc dopaminergic axons can produce
a small amplitude EPSC in dorsal striatum MSNs (Tritsch et al.,
2012). However, using a similar optogenetic approach, others
report that glutamate and DA are only coreleased in the ven-
tral, but not dorsal striatum (Stuber et al., 2010). Both of these
studies were performed while recording fromMSNs, and the elec-
trophysiological significance of SNc-derived glutamate on ChI
excitability has not yet been reported. Due to the close proxim-
ity between MSNs and ChIs, one would also expect an influence
of this source of glutamate on ChIs (Dimova et al., 1993; Li et al.,
2002). In this case, the loss of SNc projections in PD may impact
the degree to which glutamate modifies ChI activity.
Serotonergic (5-HT) projection neurons from the dorsal raphe
nucleus also express glutamate-like immunoreactivity. In culture,
5-HT cells form glutamatergic autapses, indicating that 5-HT
projectionsmay functionally co-release glutamate (Nicholas et al.,
1992; Johnson and Yee, 1995). The extent to which changes in
5-HT transmission are associated with altered striatal glutamater-
gic signaling is unknown, but this may contribute to striatal
dysfunction in mood disorders. SSRI treatment of depression
will prolong the action of synaptically released 5-HT, and may
lead to presynaptic inhibition through autoreceptors. This may
alter local excitation via co-released glutamate to decrease striatal
excitation.
Striatal ChIs also co-release glutamate with ACh (Higley
et al., 2011). One isoform of the vesicular glutamate transporter,
VGLUT3, is highly expressed in ChIs, and evidence suggests co-
expression of this transporter with the vesicular ACh transporter
on the same synaptic vesicles. These transporters act syner-
gistically to optimize vesicular loading of ACh and glutamate
(Nelson et al., 2014a). Vglut3 knock-out mice have a hypocholin-
ergic striatum, presumably due to a decrease in loading of both
glutamate and ACh into vesicles, and also due to less excita-
tory drive onto synaptically connected ChIs (Gras et al., 2008).
The functional consequences of these non-thalamic/non-cortical
sources of glutamatergic drive onto ChIs have not been studied
in depth.
GLUTAMATE – METABOTROPIC RECEPTORS
Glutamate also mediates long-term modulation of ChIs via
metabotropic glutamate receptors (mGluRs). Excitatory group
I mGluRs, which include mGluR1 and mGluR5, are highly
expressed on ChIs (Tallaksen-Greene et al., 1998; Bell et al., 2002;
Conn et al., 2005), and application of group I agonists induce
excitation (Calabresi et al., 1999; Pisani et al., 2001; Berg et al.,
2007). This excitation is mediated by a combination of cation
currents through TrpC channels downstream of Gqα, as well
as inhibition of the chloride activated K+ channel Slo2.1 (Berg
et al., 2007). The group II mGluRs, which consist of mGluR2 and
mGluR3, decrease excitability by inhibiting AC through activa-
tion of Gi/oα (Diraddo et al., 2014). mGluR2, mRNA expression
on ChIs (Testa et al., 1994; Bell et al., 2002) indicate that agonists
of these receptors would theoretically decrease cell excitability.
However, group II mGluRs are more involved in the modula-
tion of synaptic inputs onto ChIs, as activation of these receptors
results in no change in membrane potential, but decreases the
amplitude of both excitatory and inhibitory synaptic inputs onto
ChIs (Pisani et al., 2002; Martella et al., 2009). Of the group III
mGluRs, only mGluR7 is expressed on ChIs, at a prevalence of
38% with no expression of mGluR4, 6, or 8. As with group II
mGluRs, group III mGluRs decrease presynaptic release probabil-
ity by inhibition of the AC pathway (Bell et al., 2002). Although
rapid ChI excitation and inhibition are mediated by ionotropic
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Table 2 | Neurotransmitter systems and their effects on ChI activity.
Neurotransmitter Source Postsynaptic Effect on ChI
receptor targets
GABA MSN
PLTS interneurons
SNc (?)
GABAA GABAA: Inhibition DeBoer and Westerink, 1994
Glutamate Intralaminar thalamic nuclei
Sensorimotor cortex
SNc
Raphe nucleus
ChI
GluR1, 2, 4
GluN1, 2D
Kainate
AMPA, NMDA, Kainate: Excitation Calabresi et al., 1998b; Vorobjev
et al., 2000; Cepeda et al., 2001
mGluR1,5: Excitation Calabresi et al., 1999; Pisani et al., 2001; Berg
et al., 2007
mGluR2: Inhibition Martella et al., 2009
mGluR7: No direct effect Bell et al., 2002
Dopamine SNc
DA-ergic interneurons
D1 (low levels)
D2
D5
Increased excitation Aosaki et al., 1998; Centonze et al., 2003; Ding
et al., 2011b or
Decreased excitation Deng et al., 2007a; Chuhma et al., 2014
5-HT Raphe nucleus 5-HT2 Increased excitation Blomeley and Bracci, 2005
5-HT6 Excitation Bonsi et al., 2007
5-HT7 Excitation Bonsi et al., 2007 or No effect Blomeley and Bracci, 2005
Histamine TMN
Mast cells
H1
H2
H3
Depolarization and action potential firing Bell et al., 2000
Substance P D1 MSNs NK1 Depolarization, inward shift in holding current Aosaki and
Kawaguchi, 1996
Increased ACh release Arenas et al., 1991; Preston et al., 2000
Enkephalin D2 MSNs DOR Decreased excitation Mulder et al., 1984
KOR Decreased excitation Schoffelmeer et al., 1997
No effect on K+ induced ACh release Arenas et al., 1990; Jackisch
et al., 1993
MOR Decreased excitation Ponterio et al., 2013
Dynorphin D1 MSNs KOR Excitation at low concentrations of agonist Crain and Shen, 1996
Inhibition at higher concentrations of agonist Gross et al., 1990
Noradrenaline Locus coeruleus β1 Depolarization, increased action potential firing Pisani et al., 2003
Adenosine Degradation of ATP A1 Inhibition of ACh release Brown et al., 1990
A2A Increased ACh release Kurokawa et al., 1994
No change in ACh release Jin and Fredholm, 1997
ATP Synaptic release P2X No change in holding current Scheibler et al., 2004
P2Y
Nitric oxide NOS+ PLTS interneurons Depolarization Centonze et al., 2001
Summary of the neurotransmitter systems and other neuromodulators involved in the regulation of ChI activity. “?” denotes potential yet untested source of
neurotransmitter release.
receptors, it is important to consider that glutamate can have long
termmodulatory effects on ChI excitability via mGluR activation.
DOPAMINE
In addition to GABA and glutamate, there are a number of
other neurotransmitter systems that affect ChI activity. Striatal
dopamine levels are the highest of any region in the brain and it
is a principal determinant of striatal function. The predominant
source of dopaminergic innervation of the dorsal striatum is
A9 neurons—neurons which have cell bodies in the SNc and
project broadly into the striatum, forming hundreds of thou-
sands of synaptic connections per neuron (Kubota et al., 1987;
Chang, 1988; Arbuthnott and Wickens, 2007; Moss and Bolam,
2008; Matsuda et al., 2009; Threlfell and Cragg, 2011). Although
synaptic connections toMSNs are well documented, some reports
demonstrate dopamine cells synapse onto ChAT positive cells
(Hattori et al., 1976) while others report that dopamine modu-
lates ChIs through volume transmission (Lehmann and Langer,
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FIGURE 1 | Network connectivity of dorsal striatal cholinergic
interneurons. Simplified schematic illustrating some of the afferent
synaptic inputs onto ChIs. Arrow heads indicate excitation, while
perpendicular lines indicate inhibition. Dotted lines indicate a weak
synaptic input. “?” denotes uncertain or untested inputs that are
expected by either anatomical or physiological results. References that
support afferent connections to ChIs can be found in the text and
Table 2.
1983). These nigral dopaminergic neurons may exist in 4 dif-
ferent activity states. The tonically active state is independent
of excitatory drive, as the neurons will fire at a rate of around
3Hz in vivo or ex vivo in a slice preparation (Grace and Bunney,
1984; Hyland et al., 2002; Zhou et al., 2006; Ding et al., 2011a;
Henny et al., 2012; Guatteo et al., 2013). They also can transi-
tion to burst activity with excitatory inputs increasing activity to
around 20Hz (Grace and Bunney, 1984; Hyland et al., 2002). In
addition to these two active states, the cells may exist in one of
two silent states, either hyperpolarization below action potential
threshold, or depolarization block. Activity of these neurons is
crucially important to normal striatal function (Gasser, 2009).
Postsynaptically, the majority of ChIs express D2 and D5
receptors with only about 20% of the neurons expressing low lev-
els of D1 receptors (Dawson et al., 1988; Bergson et al., 1995; Yan
et al., 1997). D2 receptors generally decrease neuronal exitabil-
ity through activation of Gi/oα, which also inhibits AC activity to
decrease cAMP levels. D5 receptors are members of the D1 fam-
ily that activate AC through Gs and generally increase excitability
(Beaulieu and Gainetdinov, 2011). In the slice preparation, bath
application of DA can strongly excite ChIs (Aosaki et al., 1998;
Centonze et al., 2003; Ding et al., 2011b), however others have
reported that DA inhibits ChIs by prolonging slow afterhyper-
polarization duration (Deng et al., 2007a), and that optogenetic
activation of DA terminals induces a pause in ChI firing (Chuhma
et al., 2014). It was also reported that amphetamine-induced
increases in striatal DA rhas no effect on ACh efflux in vivo
(Abercrombie and DeBoer, 1997), implying that, under those
conditions, elevated DA does not significantly affect cholinergic
tone. Clearly, DA can affect ChI excitability, and the conditions
under which DA either excites or inhibits these neurons will
require further study.
In addition to this important extrastriatal source of DA, there
also exists a small population of striatal DA interneurons in both
primates and rodents (Dubach et al., 1987; Cossette et al., 2005;
Ibáñez-Sandoval et al., 2010). Interestingly, the number of stri-
atal TH+ cells increases following acute experimental dopamine
depletion in both rodents and primates (Tashiro et al., 1989;
Betarbet et al., 1997; Smith and Kieval, 2000; Jollivet et al., 2004).
This is potentially a compensatory mechanism designed to coun-
teract the loss of DA-ergic innervation from SNc. Strangely, the
number of striatal TH+ cells is decreased in humans with PD
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FIGURE 2 | Receptor expression on ChIs. Simplified diagram depicting a subset of known receptor classes expressed on ChIs grouped by neurotransmitter.
Values represent percent of ChIs that express the given receptor. References for receptor expression by ChIs can be found in the text and Table 2.
(Huot et al., 2007), highlighting one difference between experi-
mentally induced PD and the actual pathogenesis of the disease
in humans. These DA interneurons form inhibitory GABA-ergic
synapses with MSNs (Ibáñez-Sandoval et al., 2010). Whether or
not these TH+ interneurons make DA-ergic and/or GABA-ergic
synaptic contacts with ChIs is yet to be determined. Another
interesting question to address would be whether or not these
TH+ interneurons undergo changes in physiology that serve in
a homeostatic role in the Parkinsonian striatum. Independent of
changes in cell numbers outlined above, increased excitability fol-
lowing DA depletion may counteract low levels of striatal DA to
help maintain striatal function. This small minority of striatal
cells remains an interesting focus for future investigations.
ACETYLCHOLINE
ChIs receive synaptic inputs from other ChIs. Both nAChRs and
mAChRs are expressed at various levels on ChIs. With respect to
nAChR expression, in situ hybridization has shown that all ChIs
express mRNA for β2 subunits, about half express α7 mRNA,
while other subunit mRNAs are expressed at low levels (Azam
et al., 2003). In support of the idea that ChIs express nAChRs,
nicotine application to a slice preparation induces ACh release
(Sandor et al., 1991). Interestingly, that effect was only seen
in slices from animals that had undergone dopamine deple-
tion with 6-OHDA treatment or in the presence of the D2
receptor antagonist sulpiride. These data suggest that resolving
the nAChR-mediated ACh release requires elimination of D2
receptor mediated inhibition (Sandor et al., 1991).
ThemAChR component of AChmodulation is through activa-
tion of the Gi/o coupledM2 andM4 receptors (Weiner et al., 1990;
Smiley et al., 1999; Ding et al., 2006), thus acting as an autoin-
hibitory clamp to prevent excessive ACh release. No co-expression
of M1 and ChAT is observed in the striatum (Dawson et al., 1990;
Alcantara et al., 2001).
Synchronized activity in ChIs is observed following presenta-
tion of behaviorally salient stimuli (Apicella et al., 1997; Ravel
et al., 1999). Although this synchronous firing has been linked
to coordinated thalamostriatal inputs (Ding et al., 2010), ChI
projections to other ChIs may also contribute to this syn-
chrony through positive feedback control to coordinate strong
increases in ACh. Whether or not nAChR mediated transmission
contributes to ChI-ChI signaling has yet to be reported.
SEROTONIN
Serotonin is a major determinant of ChI excitability. 5-HT-ergic
projections originate from the raphe nucleus in the hind brain.
These cells fire tonically at a rate of about 1–2Hz (Innis and
Aghajanian, 1987; Sprouse et al., 1989; Haj-Dahmane et al., 1991),
releasing 5-HT into many brain areas including the striatum.
5-HT has an overall direct excitatory effect on ChIs, increasing
action potential firing and membrane depolarization (Blomeley
and Bracci, 2005; Bonsi et al., 2007). Activation of the Gq-coupled
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5-HT2 receptors increases excitability due to a decrease in the
amplitude of both the slow and medium afterhyperpolarization
(AHP) (Blomeley and Bracci, 2005). It has not been examined if
5-HT receptor classes 1A, 3, or 4 are expressed on ChIs, however
selective agonists of these receptor classes do not induce changes
in ChI excitability (Blomeley and Bracci, 2005). 5-HT6 activa-
tion excites ChIs (Bonsi et al., 2007). The contribution of the
5-HT7 receptor to excitation is debated, as Blomeley and Bracci
(2005) reported no effect, while Bonsi et al. (2007) observed
depolarization.
HISTAMINE
Histamine (HA) is a neurotransmitter that was first identified as a
peripheral vasodilator with an effect on respiratory patterns and
muscle tone (Dale and Laidlaw, 1910). Originally described in the
brain in 1984, HA immunoreactive fibers were found to project
widely throughout the brain including the striatum (Haas et al.,
2008). HA-ergic cell bodies reside only in a small region of the
posterior hypothalamus, the tuberomamillary nucleus (Panula
et al., 1984; Blandina et al., 2012). Histamine is also produced by
mast cells (Schwartz et al., 1986).
HA can act on 4 different types of G-protein coupled receptors,
H1 through H4 (Parsons and Ganellin, 2006). These receptors are
widely expressed, but only H1, H2, andH3 are highly expressed in
the striatum, with H1 and H2 expressed on ChIs, and the autore-
ceptor H3 being expressed presynaptically on HA-ergic terminals.
H1 and H2 are excitatory, coupling to Gq and Gs respectively,
while the inhibitory H3 receptor is coupled with Gi (Timmerman,
1989; Haas et al., 2008). HA application has the net result of
depolarization of ChIs, presumably acting through by H1 recep-
tors (Bell et al., 2000). In the ventral striatum, ACh overflow is
increased following H1 activation, while blockade of H2 increases
ACh overflow, presumably through activation of H2 on GABA
interneurons (Prast et al., 1999b). The same group found an
increase in ACh overflow with concurrent H3 activation, an effect
mediated by presynaptically expressed GABA interneurons (Prast
et al., 1999a).
OPIOIDS
ChIs are also sensitive to opioidergic modulation. δ, κ, and μ opi-
oid receptors (DOR, KOR, and MOR, respectively) are the three
major classes of opioid receptors in mammals. These receptors
inhibit cell activity through coupling with Gi/o proteins (Mansour
et al., 1994; Tso andWong, 2003), and are activated endogenously
by a number of tightly regulated peptides. The endogenous opi-
oid enkephalin activates DORs, and is produced by D2 expressing
indirect pathway MSNs. mRNA for DORs is expressed in striatal
ChIs (Le Moine et al., 1994), and activation of these receptors
decreases ACh release (Mulder et al., 1984). The low number
of synaptic connections between enkephalinergic cells and ChAT
positive cells (Martone et al., 1992) suggests that enkephalin may
only minimally inhibit ChI activity endogenously, but this does
not preclude the possibility of volume transmission. Systematic
investigation of endogenous DOR effects on ChI excitability has
not been reported.
KOR is another major class of opioid receptors in the striatum.
The endogenous opioid dynorphin is produced by D1 expressing
direct pathway MSNs, and activates KORs. Like DORs, KORs
are widely expressed in the striatum (Fallon and Leslie, 1986;
Mansour et al., 1994). Compared to the DOR or MOR, the KOR
receptor can be associated with Gi/o as well as Gs. This bipo-
lar effect of KOR activation is concentration dependent. At very
low, subnanomolar concentrations of agonist, KOR preferably
couples to Gs (Crain and Shen, 1996), but increasing the concen-
tration results in the activation of signaling cascades downstream
of Gi/o (Gross et al., 1990; Claye et al., 1996). Thus, depending
on the level of striatal dynorphin, ChIs may either increase or
decrease their excitability. KOR activation decreases ACh release
in the striatum (Mulder et al., 1991; Schoffelmeer et al., 1997),
however, different studies showed no effect of KOR activation
on ACh release (Arenas et al., 1990; Jackisch et al., 1993). These
apparently contradictory findings could result from the bipha-
sic dose-dependent intracellular coupling of the KOR. It is also
possible that the KOR effects on ACh release occur through indi-
rect modulation, as there has not been a direct demonstration of
co-localization of KOR with ChAT expression in striatum, nor
is there direct electrophysiological evidence of KOR expression
on ChIs.
The MOR is also coexpressed on ChAT positive striatal cells,
however with tremendous diurnal variation, fluctuating from
30% coexpression in the daytime to a peak of 80% coexpression
in the afternoon (Jabourian et al., 2005). Activation of MOR by
exogenous DAMGO decreases ChI firing (Ponterio et al., 2013).
MOR-inhibition of ACh release lowers the DA release proba-
bility in striatum by limiting activation of presynaptic nAChRs
(Britt and McGehee, 2008). Endomorphin-1 (EM-1), an endoge-
nous agonist at the MOR, shows only weak immunoreactivity
in the striatum. EM-1 may be co-released by histaminergic neu-
rons, as the EM-1 immunoreactivity signal is very prominent
in the posterior hypothalamus (Martin-Schild et al., 1999). In
addition, some endogenous agonists have overlapping affinity for
different opioid receptor classes, such as Leu-enkephalin, which
activates both DORs, and MORs at physiological concentrations
(Jabourian et al., 2005).
TACHYKININS
Tachykinins are another class of neuropeptides expressed in
the striatum. In addition to producing GABA and dynorphin,
D1-expressing MSNs also express the tachykinin Substance P
Terminals that contain Substance P. form synaptic connections
with ChIs. Substance P. is a potent activator of NK1 receptors,
which are expressed by ChIs (Bolam et al., 1986; Richardson
et al., 2000). Activation of NK1 results in excitation (Aosaki and
Kawaguchi, 1996) and increased ACh release (Arenas et al., 1991;
Preston et al., 2000).
EFFERENT CONNECTIONS OF ChIs
Even though the ChIs make up a small fraction of cells in
the striatum, they possess a large synaptic arbor and thus
send ACh projections broadly throughout the striatum. As
such, changes in ChI physiology influence a multitude of
postsynaptic targets by activation of nicotinic and muscarinic
ACh receptors. This section addresses the effects of ACh
neurotransmission.
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NICOTINIC ACETYLCHOLINE RECEPTORS
Nicotinic acetylcholine receptors (nAChRs) are ligand-gated,
pentameric ion channels that are activated by endogenous ACh,
exogenous nicotine, or other ligands. nAChRs can be expressed
both pre and postsynaptically, where they induce depolarization
and increase excitability. Presynaptic nAChRs enhance release
of several different neurotransmitter types (MacDermott et al.,
1999). The subunits that are assembled into neuronal nAChRs
include α2-α10 and β2-β4 (Patrick et al., 1993; McGehee and
Role, 1995; Dani, 2001). They can be composed of homomeric or
heteromeric subunit combinations, which determine character-
istic pharmacological and biophysical properties of the receptor
(Fenster et al., 1997; Gotti et al., 2006b). In the striatum, the
most common nAChR subunits are the α4, α6, α7, β2, and β3,
although other subunits are present at lower levels (Quik et al.,
2007). Generally, nAChR activation induces rapid depolarization,
but Ca2+ entry, particularly through homomeric α7 nAChRs can
lead to rapid changes in neurotransmitter release or long term
changes in cellular function through activation of Ca2+ depen-
dent intracellular cascades, such as altered transcription through
pCREB activation (Mulle et al., 1992; Chang and Berg, 2001; Hu
et al., 2002; Wu et al., 2009; Del Barrio et al., 2011).
MUSCARINIC ACETYLCHOLINE RECEPTORS
In comparison to the rapid, excitatory effect of nAChR activa-
tion, mAChR activation serves a more long-term modulatory
role. Activation of mAChRs can either increase or decrease cell
excitability. A total of 5 subtypes of mAChRs have been isolated
and cloned, but they are generally divided into 2 classes based
on differences in their intracellular signaling cascades. The exci-
tatory mAChRs, consisting of M1, M3, and M5, couple to Gq/11
and induce activation of the phospholipase C pathway (Lin et al.,
2004). The inhibitory receptors, M2, and M4, couple to Gi/o
proteins and decrease activity of adenylyl cyclase (Wess, 1996).
All 5mAChRs are expressed in the striatum (Yan et al., 2001),
however M1 and M4 are more heavily expressed than other iso-
forms, with a small presence of M2 and very low levels of M3
and M5 expression (Yasuda et al., 1993). Muscarinic receptors
are not limited to somatic expression, as terminal expression of
mAChRs serves to modulate neurotransmitter release probability.
Expression of M2 receptors on ChI terminals serves an autoin-
hibitory role (Hersch et al., 1994). Additionally, neurotransmitter
release at incoming afferents can be sensitive to mAChR modu-
lation, as these mAChRs can receive synaptic inputs from ChIs.
Because mAChR activation can either increase or decrease cell
excitability, the net effect of ACh release depends on the pat-
terns of postsynaptic mAChR expression. For each major striatal
postsynaptic target, both the nicotinic and muscarinic effects on
neuronal excitability will be addressed.
MEDIUM SPINY NEURONS
GABA-ergic MSN projection neurons are the sole output of the
striatum. Direct activation of AChRs on MSNs therefore repre-
sent a direct effect of ACh on striatal output. MSNs are generally
believed to lack nAChRs (Matsubayashi et al., 2001; Luo et al.,
2013), although Liu et al. (2007) reports that direct activation of
nAChRs on MSNs by nicotine induces depolarization. This direct
nAChR modulation of MSN activity has not been explored in
depth, as the evidence thatMSNs express nAChRs is quite limited.
Interestingly, lesion studies indicate that only about 20% of α4β2
nAChRs are expressed on DA terminals (Quik and Wonnacott,
2011). Thus, the contribution of these receptors to striatal cir-
cuitry likey involves expression on GABAergic interneurons and
presynaptic projections from a range of cell types. Resolving the
complete physiological role of striatal α4β2 receptors is a topic of
ongoing investigations.
Themajority of studies of ACh-mediatedmodulation ofMSNs
focuses on mAChR activation. Bath application of the mAChR
agonist carbachol increases MSN excitation in the absence of
synaptic input, both in a slice preparation and in dissociated cell
culture (Hsu et al., 1996; Galarraga et al., 1999). Twomechanisms
have been proposed to explain this excitation. One involves an
M1 mediated decrease in the inhibitory KCNQ potassium (Kv7)
current (Shen et al., 2005), while the other an M1 mediated inhi-
bition of Ca2+ entry through N and P/Q type channels, which
in turn decreases the duration of the AHP (Pérez-Garci et al.,
2003; Perez-Rosello et al., 2005). Neither of these studies differ-
entiates between the direct and indirect pathway MSNs, and the
mechanisms could differ between these cell types. Inhibitory M4
receptors are expressed on a subpopulation of MSNs (Bernard
et al., 1992), and functional electrophysiological evidence suggests
that M4 decreases Ca2+ influx to decrease excitability (Howe and
Surmeier, 1995). Direct pathway MSNs express both M1 and M4,
while indirect pathway MSNs express M1. Less than half of indi-
rect pathway MSNs express M4 (Bernard et al., 1992; Yan et al.,
2001). Both classes of MSNs would be excited with M1 activation,
but the differential expression pattern of the inhibitory M4 could
mean that ACh influences the two classes of MSNs in opposing
directions.
GABA-ERGIC INTERNEURONS
In addition to directly acting on MSNs, ACh can also modify
striatal output through receptors on GABA interneurons that
project to MSNs. Optogenetic activation of cholinergic cells pro-
duced IPSCs and IPSPs in MSNs that were inhibited by nAChR
blockade. This microcircuit is believed to be a disynaptic con-
nection, consisting of nAChR-expressing GABA interneurons that
are activated by ACh, which then release GABA onto MSNs
(English et al., 2011). The GABA interneurons that contribute
to this inhibition of MSNs are likely the parvalbumin-expressing
FSIs (Chang and Kita, 1992) and/or the NPY-expressing PLTS
interneurons (English et al., 2011). However, English and cowork-
ers did not observe an involvement of FSIs in the ChI-MSN
interaction. Consistent with nAChR activation leading to elevated
striatal GABA, inhibition of α7 receptors resulted in a decrease in
striatal GABA in awake behaving animals (Beggiato et al., 2013),
while activation of α7 nAChRs increases GABA levels (Campos
et al., 2010).
Muscarinic receptor activation of GABA interneurons that
project to MSNs can influence striatal output. Subcellular local-
ization of the M2 receptor has been demonstrated in the NPY+
PLTS interneurons (Bernard et al., 1998). Consistent with this
result, ACh decreases striatal GABA release (Marchi et al., 1990).
More specifically, this is mediated by an inhibitory mAChR, as
Frontiers in Synaptic Neuroscience www.frontiersin.org October 2014 | Volume 6 | Article 22 | 11
Lim et al. Striatal cholinergic interneuron connectivity
muscarine decreases GABA release onto MSNs (Sugita et al.,
1991). Thus far, there are no reports of M1 receptor expres-
sion on GABA interneurons, but it is possible that M1-mediated
enhancement of GABA output from one of the other interneuron
subtypes neurons could contribute to striatal circuitry.
GLUTAMATERGIC TERMINALS
Glutamatergic inputs into the dorsal striatum originate primarily
from the intralaminar nuclei of the thalamus and from the sen-
sorimotor cortex, with a small amount of glutamate co-released
from other terminals as well (Higley et al., 2011). nAChR expres-
sion on glutamatergic terminals provides amechanism for cholin-
ergic enhancement of excitatory drive onto MSNs. Increased
glutamate release through activation of presynaptic nAChRs has
been observed in brain regions such as the hippocampus, medial
habenula, olfactory bulb and human neocortex (McGehee et al.,
1995; Gray et al., 1996; Fisher and Dani, 2000; Girod et al., 2000;
Marchi et al., 2002). Glutamate release probability is also modu-
lated by nAChRs in the striatum (Kaiser and Wonnacott, 2000).
In vivo microdialysis studies demonstrate that α7 nAChR activa-
tion in striatum increases glutamate release (Campos et al., 2010).
α7 nAChR antagonism decreases glutamate release (Carpenedo
et al., 2001), indicating that baseline ACh levels contribute to glu-
tamatergic tone. Because the homomeric α7 subtype is highly
Ca2+ permeable compared to other nAChRs stoichiometries,
Ca2+ entry through these receptors may lead directly to enhanced
neurotransmitter release (Gray et al., 1996). Activation of the
α4β2∗ subtype also increases glutamate release onto MSNs (Xiao
et al., 2009). As glutamatergic inputs originate from various neu-
ronal types and brain regions, differential expression of nAChR
stoichiometries may allow ChIs to amplify glutamate inputs
differentially.
In contrast, activation of mAChRs negatively modulates stri-
atal glutamate release. In field potential recordings, a mAChR
agonist suppressed corticostriatal glutamatergic transmission
(Malenka and Kocsis, 1988). Increasing mAChR signaling either
by increasing ChI firing rates, or exogenous agonist application
decreases excitatory drive onto MSNs (Calabresi et al., 1998a;
Pakhotin and Bracci, 2007; Pancani et al., 2014). Muscarinic
modulation of glutamatergic terminals occurs through M2 or
M4 receptor activation, as mRNA and protein levels for both
mAChRs are observed at high levels in striatal somata as
well as terminals (Levey et al., 1991; Hersch et al., 1994).
M2 or, interestingly enough, M3 activation results in paired
pulse facilitation, indicating that mAChR activation decreases
glutamate release probability (Hernández-Echeagaray et al.,
1998; Ding et al., 2010). The change in release probability is
observed in both corticostriatal afferents and thalamostriatal
afferents, and when recording from both direct and indirect
MSNs, indicating that regardless of the origin of the termi-
nal or the post-synaptic target, release probability at gluta-
matergic terminals is decreased with mAChR activation (Ding
et al., 2010). In agreement with these observations, intras-
triatal injections of an M2-selective antagonist increases glu-
tamate overflow (Smolders et al., 1997), providing evidence
that tonic levels of ACh contribute to striatal glutamate tone.
Additionally, glutamate release is downregulated via mAChR
activation (Dodt and Misgeld, 1986). ChIs are thus in a posi-
tion to regulate excitatory inputs to MSN, both rapidly by act-
ing on nAChRs, and more slowly and persistently via mAChR
activation.
DOPAMINERGIC TERMINALS
ACh profoundly modulates DA release in the striatum. In a
slice preparation, optogenetic activation of ChIs increases evoked
DA release. The quantity of DA released is dependent on fre-
quency of stimulation, and requires synchronous ChI cell acti-
vation as well as activation of β2-containing nAChRs expressed
on dopaminergic terminals (Cachope et al., 2012; Threlfell et al.,
2012). Although the physiological conditions that coordinate syn-
chronous firing of large numbers of ChIs are unknown, cross-talk
between ChIs may facilitate simultaneous firing of these neurons
to enhance DA release.
Dopaminergic terminals express α4 and β2 subunits at high
levels, along with α5, α6, α7, and β3 subunits at variable lev-
els (Le Novère et al., 1996; Sharples et al., 2000; Jones et al.,
2001; Klink et al., 2001; Quik et al., 2003; Grady et al., 2007;
Keath et al., 2007). Nicotinic agonists increase the efflux of DA
in striatal tissue, as measured by microdialysis (Puttfarcken et al.,
2000; Campos et al., 2010), and as expected, nAChR antagonists
decrease DA efflux by interfering with the effects of local ACh
activation of presynaptic nAChRs on DA terminals (Wonnacott
et al., 2000; Grady et al., 2007). There is evidence that enhance-
ment of DA release by exogenous activation of nAChRs requires
glutamatergic signaling (Garcia-Munoz et al., 1996; Wonnacott
et al., 2000), but enhancement of DA release by coordinated ACh
release from ChIs is not dependent upon glutamate transmission
(Threlfell et al., 2012). Additionally, striatal dopaminergic termi-
nals also corelease GABA. In a recent study, optogenetic activation
of ChIs produces a GABAA receptor mediated synaptic response
in MSNs. Pharmacological blockade of α4 nAChRs inhibits this
GABA current, suggesting that striatal nAChRs regulate GABA
levels via modulation of release probability from DA terminals
(Nelson et al., 2014b).
The expression of nAChRs on DA terminals not only enhances
DA transmission, chronic agonist exposure, such as that achieved
in tobacco users can shift DA release probability to suppress
release during low frequency activity, but maintain or enhance
release during burst firing (Zhou et al., 2001; Rice and Cragg,
2004; Zhang and Sulzer, 2004). These observations were obtained
using high resolution fast-scan cylclic voltammetry to assess
extracellular DA levels, and they suggest that nicotine may
enhance the impact of high frequency DA neuron activity to
effectively increase the salience of environmental stimuli. Recent
in vivo investigations suggest that a chronic nicotine exposure
model, which mimics the daily pattern of nicotine exposure
by smokers (2 weeks via drinking water), results in a down-
regulation of electrically stimulated DA release due to persistent
desensitization of nAChRs on DA terminals (Koranda et al.,
2014). This observation extends the results seen in other prepara-
tions including brain slices and non-human primates (Perez et al.,
2012, 2013; Exley et al., 2013). Together, these findings have led
to the intriguing speculation that the reported protective effects
of smoking against PD may result from an adaptation in striatal
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circuitry to lower DA levels, thus delaying the onset of symptoms
(Koranda et al., 2014).
Exogenous nicotine affects striatal dopamine in interesting and
sometime counterintuitive ways, as the interplay between nAChR
activation and desensitization can lead to contradictory effects.
In contrast, endogenous ACh from ChIs is rapidly degraded by
acetylcholinesterase, which is expressed at remarkably high lev-
els in striatum. As alluded to above, synchronous ChI activation
can have profound effects on DA release in striatum, through the
coordinated activation of presynaptic nAChRs on DA terminals
(Threlfell et al., 2012). This study from the Cragg laboratory used
optogenetic stimulation to coordinate ChI activity selectively to
demonstrate this phenomenon. This is relevant to endogenous
activation of ChIs, as synchronous stimulation of these neurons
has been reported through coordination of thalamostriatal inputs
in response to salient environmental stimuli (Ding et al., 2010;
Threlfell et al., 2012).
While mAChRs are also involved in modulation of DA release,
the identity of mAChRs expressed by SNc DA cells is unclear,
as some observe M2, M4, and M5 (Vilaró et al., 1990; Levey
et al., 1991), while others report expression of only M5 recep-
tors (Weiner et al., 1990). Agreement on M5 receptor expression
suggests that dopaminergic terminals in the striatum express
this mAChR subtype. Electrophysiological evidence supports this,
as M5 KO mice show reduced oxotremorine enhancement of
potassium-stimulated dopamine release (Zhang et al., 2002). M2
receptors are also involved in tonic DA release, as intrastriatal
administration of an M2 antagonist dramatically increases DA
levels in freely moving rats (Smolders et al., 1997). Non-selective
activation of striatal mAChRs with oxotremorine increases DA
release (Lehmann and Langer, 1982; Threlfell et al., 2010), sug-
gesting that M5 activation plays a stronger role in the modulation
of DA terminals.
PLASTICITY OF THE EXCITATORY INPUTS TO CHOLINERGIC
INTERNEURONS
Activity-dependent modification of synaptic connections is
believed to be an important cellular substrate for learning and
memory. As the dorsal striatum is believed to be an important
site of action for habit formation and motor learning, it is likely
that synaptic plasticity contributes to that learning. Considerable
effort has focused on understanding the plasticity of the excita-
tory inputs to MSNs (Calabresi et al., 1996; Mahon et al., 2004;
Surmeier et al., 2007), however, LTP/LTD in ChIs has not been
explored extensively. Recording in tissue slices from dorsal stria-
tum, Suzuki et al. (2001b) demonstrated LTP in ChIs following
a 1 s, 100Hz train stimulation of the corpus callosum. This LTP
was dependent on Ca2+ entry, as intrapipette BAPTA blocked LTP
induction. The source of Ca2+ entry in these studies was not from
NMDA receptors, as NMDA blockers had no effect on LTP induc-
tion. They also found this LTP to be D5 receptor dependent, as
pharmacological blockade of D1/D5 receptors prevents the long
term maintenance of enhanced synaptic strength, whereas D2
receptor blockade did not affect LTP induction (Suzuki et al.,
2001b). Bonsi and co-workers observed a similar LTP (using
three 1 s, 100Hz trains), however they attribute LTP at these
synapses to calcium entry via L-type HVA channels, and not
to Ca2+ permeable AMPA receptors or NMDA receptors (Bonsi
et al., 2004). Using the same HFS stimulation paradigm as Bonsi
et al, Picconi and coworkers demonstrate that plasticity of ChIs
is not observed in the R6/2 mouse model of Huntington’s disease
(Picconi et al., 2006). It is not clear why a Huntington’s disease
model should lack plasticity at these synapses, which highlights
the need for better understanding of the underlying mechanisms
and functional significance of synaptic plasticity of the inputs to
striatal ChIs.
Spike-timing dependent plasticity (STDP) is another experi-
mental paradigm used to induce plasticity. In accordance with
Hebbian theory, changing the time between presynaptic activa-
tion and postsynaptic depolarization can elicit either a strength-
ening, weakening, or no change in synaptic strength. First
discovered in the cortex, examples of STDP have been observed
in other parts of the nervous system including the hippocampus,
striatum neuromuscular junction, and cerebellum (Linden et al.,
1991; Markram et al., 1997; Wan and Poo, 1999; Nishiyama et al.,
2000; Plotkin et al., 2013). To date, only one group has reported
STDP in ChIs. Fino and colleagues observed bidirectional plas-
ticity in a majority of ChIs—Post-pre stimulation elicited an
LTP in some cells and LTD in others, while pre-post stimulation
results in only LTD. Using pharmacology, they found that both
forms of plasticity depend upon mGluR activation (Fino et al.,
2008). These findings contrast with the Suzuki study where HFS
induced-LTP was insensitive to mGluR blockade (Suzuki et al.,
2001b). Additionally, post-pre stimulation plasticity was inhibited
by NMDA receptor blockade, suggesting that HFS induced-LTP
occurs by another mechanism. Further exploration into LTP/LTD
of the excitatory inputs to ChIs represents an exciting field of
study, as changes in synaptic strength here may contribute to
motor skill learning and habit formation.
SUMMARY
Even though ChIs only make up 1–2% of all striatal cells, they
send dense projections throughout the striatum. ACh can affect
the output of the striatum directly or indirectly, and a wide vari-
ety of neurotransmitter systems can influence the activity of these
cells. Given that ChIs are in a position to integrate synaptic inputs
andmodulate the output of the striatum, understanding the phys-
iology of these cells will contribute to our knowledge of striatal
function.
ChIs receive afferent inputs from a wide variety of sources
which can arise either locally from within the striatum, or from
brain regions as distant as the brainstem. Some of these neuro-
transmitter systems alter cellular excitability rapidly through their
actions on ionotropic receptors, producing rapid electrical sig-
nals on a millisecond time scale. These changes in membrane
properties affect the firing activity of the ChIs, and given the
hundreds of thousands of synaptic contacts formed by each ChI,
several other cell types are influenced by changes ACh release. The
inherent membrane properties of ChIs allows them to be eas-
ily modified in either direction during neurotransmitter release:
their depolarized resting membrane potential allows excitatory
neurotransmitters to easily enhance action potential firing rate,
and considering their tonic activity, inhibitory neurotransmitters
will inhibit firing, reducing total cholinergic tone. Thus, because
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these cells are resting at some intermediate state of activity, they
are sensitive to incoming afferents. In addition to the ionotropic
receptors on these cells, ChIs express a wide variety of GPCRs.
Activation of GPCRs can have a multitude of cellular effects,
including the opening of ion channels, changes in plasticity or
protein transcription (Altier, 2012; Rojas and Dingledine, 2013).
The long time course of the signaling cascades downstream of
GPCR activation could indicate that a temporary increase in neu-
rotransmitter activity may lead to long-lasting modifications in
ChI physiology that increases or decreases the cellular response
to other incoming afferents. Given the sensitivity of these cells to
various synaptic inputs, understanding ChI connectivity provides
insight into the striatal network.
ACh has a wide variety of effects following release, either by
directly activating receptors on postsynaptic cells or indirectly via
the modulation of neurotransmitter release at terminals. Changes
in striatal cholinergic tone will thus result in a complex series
of downstream effects which ultimately may affect the striatal
output neurons. Considering the multiple ACh-sensitive neu-
rotransmitter systems that are involved in the striatal network,
changes in receptor function or expression on any class of cells
may result in a shift in the balance of these systems, potentially
resulting in dysfunction. Understanding the nature of synaptic
connectivity and the location of receptor expression therefor has
a direct connection with human pathology. Using this knowledge
in conjunction with an understanding of the changes that occur in
disease, we can work toward the development of novel therapies
that are aimed at counteracting neurotransmitter dysregulation.
Often times, we oversimplify the nature of the neurotrans-
mitters released at a given terminal, neglecting the co-release of
other neurotransmitters whose post-synaptic effects can differ
from the primary neurotransmitter. Although there is evidence
that co-release occurs, very few have looked in detail at the func-
tional consequences of multiple transmitter release, or whether or
not these neurotransmitters are released in sufficient amounts to
contribute to cell physiology.
New genetic techniques can improve our understanding of
striatal neurotransmission in both the normal and abnormal
brain. Optogenetic manipulation of excitability in specific neu-
ronal subtypes is providing important insights into connectiv-
ity throughout the nervous system. This robust technology has
advantages over other methods of exogenous neural control and
certainly provides a means to explore ChI efferent and afferent
connections, as well as the nature of the neurotransmitter pheno-
types that influence the excitability of these neurons. Extending
these methods to in vivo analyses can help provide causal links
between synaptic information and behavior.
CLARITY is a potentially groundbreaking new technique that
allows high resolution visualization of subcellular structures such
as individual synapses in the whole brain (Chung and Deisseroth,
2013). Because the preparation for CLARITY removes brain
lipids, antibodies can easily permeate the entirety of the brain,
permitting the resolution of the striatal connectome in total.
This anatomical information will precisely elucidate the synaptic
connectivity between striatal cell types.
Ultimately, ongoing efforts to improve our understand-
ing of striatal ChIs will provide valuable insights into the
physiology of this important brain area and help identify new
pharmacotherapies for striatal disorders.
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